Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Mental Illness Develops in 20% of Elderly Prostate Cancer Patients

Mental Illness Develops in 20% of Elderly Prostate ...

Risk is greater in patients managed with watchful waiting than in those who undergo radical treatment.

Focal Prostate Cancer Therapy Safe, Feasible

Focal Prostate Cancer Therapy Safe, Feasible

In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.

MRI Highly Accurate in Detecting Significant Prostate Cancer

MRI Highly Accurate in Detecting Significant Prostate ...

Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.